Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Tumor microenvironment and the response to anticancer therapy.

Brown JM.

Cancer Biol Ther. 2002 Sep-Oct;1(5):453-8. Review.

PMID:
12496469
2.

Tumor hypoxia in cancer therapy.

Brown JM.

Methods Enzymol. 2007;435:297-321.

PMID:
17998060
3.

Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.

Brown JM.

Mol Med Today. 2000 Apr;6(4):157-62. Review.

PMID:
10740254
4.

Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?

Vordermark D, Brown JM.

Strahlenther Onkol. 2003 Dec;179(12):801-11. Review.

PMID:
14652668
5.

Exploitation of the HIF axis for cancer therapy.

Escuin D, Simons JW, Giannakakou P.

Cancer Biol Ther. 2004 Jul;3(7):608-11. Epub 2004 Jul 29. Review.

PMID:
15197342
6.

Hypoxia inducible factor as a cancer drug target.

Welsh SJ, Powis G.

Curr Cancer Drug Targets. 2003 Dec;3(6):391-405. Review.

PMID:
14683498
7.

Tumor hypoxia: a target for selective cancer therapy.

Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M.

Cancer Sci. 2003 Dec;94(12):1021-8. Review.

8.

Hypoxia: targeting the tumour.

Boyle RG, Travers S.

Anticancer Agents Med Chem. 2006 Jul;6(4):281-6. Review.

PMID:
16842231
9.

[Can tumor hypoxia be turned into a chemotherapeutic advantage?].

Trédan O, Grantab R, Dumontet C.

Bull Cancer. 2008 May;95(5):528-34. doi: 10.1684/bdc.2008.0637. Review. French.

10.

YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.

Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW.

J Natl Cancer Inst. 2003 Apr 2;95(7):516-25.

PMID:
12671019
11.

Hypoxia inducible factor-1alpha as a cancer drug target.

Powis G, Kirkpatrick L.

Mol Cancer Ther. 2004 May;3(5):647-54. Review.

12.

Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.

De Ridder M, Van Esch G, Engels B, Verovski V, Storme G.

Bull Cancer. 2008 Mar;95(3):282-91. doi: 10.1684/bdc.2008.0592. Review.

13.

Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.

Shi M, Guo XT, Shu MG, Chen FL, Li LW.

Med Hypotheses. 2007;69(1):33-5. Epub 2007 Feb 5.

PMID:
17280792
14.

Inhibiting hypoxia-inducible factor 1 for cancer therapy.

Melillo G.

Mol Cancer Res. 2006 Sep;4(9):601-5. Epub 2006 Aug 28. Review.

15.

The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

Brown JM, Giaccia AJ.

Cancer Res. 1998 Apr 1;58(7):1408-16. Review.

16.

Tirapazamine: a novel agent targeting hypoxic tumor cells.

Reddy SB, Williamson SK.

Expert Opin Investig Drugs. 2009 Jan;18(1):77-87. doi: 10.1517/13543780802567250 . Review.

PMID:
19053884
17.

Role of hypoxia-inducible factor-1alpha as a cancer therapy target.

Patiar S, Harris AL.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S61-75. Review.

18.

Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology.

Weinmann M, Welz S, Bamberg M.

Curr Med Chem Anticancer Agents. 2003 Sep;3(5):364-74. Review.

PMID:
12871083
19.

Radiation sensitization with redox modulators: a promising approach.

Rosenberg A, Knox S.

Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):343-54. Review.

PMID:
16414370
20.

Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.

Ebbesen P, Pettersen EO, Gorr TA, Jobst G, Williams K, Kieninger J, Wenger RH, Pastorekova S, Dubois L, Lambin P, Wouters BG, Van Den Beucken T, Supuran CT, Poellinger L, Ratcliffe P, Kanopka A, Görlach A, Gasmann M, Harris AL, Maxwell P, Scozzafava A.

J Enzyme Inhib Med Chem. 2009 Apr;24 Suppl 1:1-39. doi: 10.1080/14756360902784425. Review.

PMID:
19330638

Supplemental Content

Support Center